Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy.
NN6706-8282
Phase 2 other active
Quick answer
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy. for Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy. is a Phase 2 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.
- Phase
- Phase 2
- Modality
- other
- Status
- active